Idecabtagene vicleucel: questions regarding the appropriate role and cost

Br J Haematol. 2022 Jan;196(2):e15-e16. doi: 10.1111/bjh.17784. Epub 2021 Aug 16.

Authors

Kerrington Powell¹, David Russler-Germain², Vinay Prasad³

Affiliations

¹ College of Medicine, Texas A&M Health Science Center, College Station, TX, USA.
² Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
³ University of California San Francisco, San Francisco, CA, USA.

PMID: 34402527
DOI: 10.1111/bjh.17784

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Clinical Decision-Making
Disease Management
Health Care Costs
Humans
Immunotherapy, Adoptive / adverse effects
Immunotherapy, Adoptive / economics*
Immunotherapy, Adoptive / methods*
Medical Oncology / economics
Medical Oncology / methods
Prognosis
Receptors, Chimeric Antigen*
Treatment Outcome

Substances

Receptors, Chimeric Antigen
idecabtagene vicleucel